Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | INAB |
---|---|---|
09:32 ET | 274 | 1 |
09:34 ET | 1176 | 1.02 |
10:01 ET | 100 | 1.0094 |
10:03 ET | 150 | 1.01 |
10:12 ET | 230 | 1.0198 |
10:19 ET | 294 | 1.0199 |
10:21 ET | 1999 | 1.0184 |
10:26 ET | 500 | 1.0199 |
10:30 ET | 294 | 1 |
10:33 ET | 100 | 1.005 |
10:44 ET | 2500 | 1.0001 |
11:00 ET | 1400 | 1.0075 |
11:04 ET | 20929 | 0.99 |
11:18 ET | 100 | 1 |
11:33 ET | 400 | 1 |
11:45 ET | 200 | 1.0006 |
11:49 ET | 100 | 1.0096 |
12:09 ET | 423 | 1.0096 |
12:36 ET | 1445 | 0.9912 |
01:01 ET | 3171 | 1.0099 |
01:03 ET | 200 | 1.01 |
01:08 ET | 200 | 0.9901 |
01:19 ET | 5000 | 1.0099 |
01:51 ET | 1600 | 0.995 |
01:53 ET | 4404 | 0.99 |
01:55 ET | 100 | 1 |
02:08 ET | 1000 | 1.005 |
02:15 ET | 100 | 1.0094 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
IN8BIO, Inc. | 45.0M | -1.0x | --- |
NKGen Biotech Inc | 45.2M | -0.3x | --- |
Quince Therapeutics Inc | 44.5M | -1.3x | --- |
Ocean Biomedical Inc | 43.5M | -1.0x | --- |
Immuneering Corp | 42.4M | -0.8x | --- |
SensaSure Technologies Inc | 42.3M | -21.8x | --- |
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead program, INB-400, is in a Phase II clinical trial in which autologous, genetically modified gamma-delta T cells are assessed in glioblastoma (GBM). Its additional programs include Phase I trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for the treatment of patients with hematologic malignancies that are undergoing hematopoietic stem cell transplantation (HSCT). In addition, the Company’s DeltEx platform has yielded a portfolio of preclinical programs, including INB-300 and INB-500, focused on addressing acute myeloid leukemia (AML) and other solid and hematological tumor types.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $45.0M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 43.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.02 |
Book Value | $0.58 |
P/E Ratio | -1.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.